Wednesday 26 June

Thursday 27 April

Friday 28 June

 
 

Session 1: Clinical Pharmacology ---- Special Populations

Effects of Advanced Liver Disease on drug PK

G. Di Perri

Pres.

 

Age and Gender Effects on the Pharmacokinetics of Multiple Oral Doses of MK-5172

C. Reitmann

Pres.

 

Telaprevir & Adjusted dose of Ribavirin in naive CHC-G1: Efficacy And Treatment in CHC in Hemodialysis population. TARGET C Trial

P. Basu

Pres.

 

Pharmacokinetics of Simeprevir (TMC435) in volunteers with severe renal impairment

A. Simion

Pres.

 

Pharmacokinetics of Simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment

S. Ouwerkerk-Mahadevan

Pres.

 

Development and validation of a novel dried blood spot assay for the quantification of ribavirin

L. Jimmerson

Pres.

 

 

Session 2: Clinical Pharmacology ---- Development / Safety issues

Drug developement/ Regulatory issues Asia

C. Peck

Pres.

 

Simeprevir (TMC435) does not prolong the QT/QTC interval in healthy volunteers

A. Simion

Pres.

 

The Effect of Single 60 mg and 180 mg Doses of Daclatasvir on the QTc Interval in Healthy Subjects

T. Garimella

Pres.

 

Romiplostim’s Effect to Optimize SVR with Telaprevir, Ribavirin, And Peg Interferon-alfa 2a in Thrombocytopenic Cirrhotics with CHC. RESTRAINT C Trial

P. Basu

Not available

 

ABT-450/r-containing direct-acting antiviral regimens are not associated with adverse changes in serum lipids or glucose in HCV genotype 1-infected patients in the AVIATOR study

D. Cohen

Not available

 

MK-5172 Pharmacokinetic/Pharmacodynamic Relationship Between Transaminase Levels And Plasma Pharmacokinetics Following Administration Of MK-5172 With Pegylated Interferon Alfa-2B And Ribavirin (Pr) To HCV Genotype (G) 1 Treatment- Naïve Patients

L. Caro

Pres.

 

The effect of food and different meal types on the bioavailability of simeprevir (TMC435), an HCV protease inhibitor in clinical development

S. Ouwerkerk-Mahadevan

Pres.

 

 

Session 3: Clinical Pharmacology ---- modeling

Role of Population PK modeling in the area of multiple DAA’s

J. Gobburu

Not available

 

Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects

MC. Rouan

Pres.

 

A population model linking plasma and intracellular ribavirin pharmacokinetics in persons with Chronic Hepatitis C Virus

L. Wu

Pres.

 

Pharmacokinetic Modeling of the Relationship Between SVR and Plasma Concentrations of Faldaprevir or BI207127 in HCV GT1- infected Patients in SOUND-C2

S. Olson

Pres.

 

Development, validation, and application of a LC-MS/MS assay for the quantification of telaprevir and its R-isomer in plasma

X. Chen

Pres.

 

 

Session 4: Clinical Pharmacology ---- Drug Drug Interactions

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple- Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir

W. Li

Pres.

 

Evaluation of Drug Interaction Potential Between Daclatasvir and Sofosbuvir

R. Bertz

Pres.

 

Daclatasvir, an HCV NS5A Replication Complex Inhibitor, has Minimal Effect on Pharmacokinetics of Midazolam, a Sensitive Probe for Cytochrome P450 3A4

R. Bertz

Pres.

 

Lack of PK interaction between the HCV protease inhibitor MK- 5172 and methadone and buprenorphine/naloxone in subjects on opiate maintenance therapy

I. Fraser

Pres.

 

Identification and Management of Potential Drug-Drug Interactions with Boceprevir and Telaprevir

J. Langness

Pres.

 

Evaluation Of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, An NS5B Non-Nucleotide Polymerase Inhibitor, Daclatasvir And Asunaprevir In Triple Combination In HCV Genotype 1-Infected Patients

T. Garimella

Pres.

 

Metabolism and Excretion of Ledipasvir (GS-5885) in Humans

B. Kirby

Pres.

 

 
 
Virology Education -
a Medical Education company